Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
14%(1 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
7
64%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
7(77.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(7)
Terminated(2)
Other(2)

Detailed Status

Completed7
unknown2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
87.5%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (22.2%)
Phase 27 (77.8%)

Trials by Status

completed764%
unknown218%
withdrawn19%
terminated19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

NCT02352896
unknown

EPI-743 for Mitochondrial Respiratory Chain Diseases

NCT01370447
withdrawnphase_2

An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

NCT02226458
completedphase_1

EPI-743 for Metabolism or Mitochondrial Disorders

NCT01642056
completedphase_2

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

NCT02257983
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02352896Phase 2

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

Completed
NCT01370447

EPI-743 for Mitochondrial Respiratory Chain Diseases

Unknown
NCT02226458Phase 2

An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

Withdrawn
NCT01642056Phase 1

EPI-743 for Metabolism or Mitochondrial Disorders

Completed
NCT02257983Phase 2

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

Completed
NCT02104336Phase 2

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

Terminated
NCT01822249Phase 2

Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

Completed
NCT01793090Phase 2

EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment

Completed
NCT01962363Phase 2

EPI-743 in Friedreich's Ataxia Point Mutations

Completed
NCT02300753

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

Unknown
NCT01719523Phase 1

Open-Trial of EPI-743 for Adults With Tourette Syndrome

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11